Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2007; 28(03): 4
DOI: 10.1055/s-0041-1733220
Editorial

Targeted therapy in Head and Neck Cancer: Some Success But More Is Expected !

Atul Sharma
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
07 March 2022

© 2007. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med.;354 (6):567-78.
  • 2 J. Jansen, J. B. Vermorken, D. Boote, F. Joulain, A. Parthan. Cost-effectiveness analysis of the EORTC 24971 (TAX 323) trial comparing docetaxel plus cisplatin and 5-fluorouracil versus standard treatment (cisplatin and 5-fluorouracil) as induction chemotherapy followed by radiation therapy in locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, 2007 (ASCO Proceedings Part I. 2007: Vol 25, No. 18S: 6090.
  • 3 Rao R, Anil K, Bansal L et al. Survival benefit and efficacy of gefitinib in recurrent metastatic head and neck cancer. Ind J. Med & Paed Oncol 2007;28(3):5-10.
  • 4 Hong WK, Schaefer S, Issell B et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983;52(2):206-10.
  • 5 Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980– 1987.